Accord BioPharma Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02

The biosimilar for Herceptin seeks to treat several forms of HER2 cancer DURHAM, N.C., April 5, 2023 /PRNewswire/ — Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.